Optimizing the Dosage Regimen of Micafungin against <i>Candida spp</i>in HIV Positive Patients with EC Based on Mote Carlo Simulation  

作　　者：Ying Wang Jingyi Zhao Song Jiang Yinhui Yao Hainan Wen Ying Wang;Jingyi Zhao;Song Jiang;Yinhui Yao;Hainan Wen(Department of Pharmacy, The Affiliated Hospital of Chengde Medical College, Chengde, China;Department of Functional Center, Chengde Medical College, Chengde, China;Department of Clinical Laboratory, The Affiliated Hospital of Chengde Medical College, Chengde, China)

机构地区：[1]Department of Pharmacy, The Affiliated Hospital of Chengde Medical College, Chengde, China [2]Department of Functional Center, Chengde Medical College, Chengde, China [3]Department of Clinical Laboratory, The Affiliated Hospital of Chengde Medical College, Chengde, China

出　　处：《Open Journal of Preventive Medicine》2020年第6期120-125,共6页预防医学期刊（英文）

摘　　要：The objective of our study was to explore the possibility of the antifungal efficacy of various micafungin dosage regimens against <i>Candida spp</i> in HIV positive patients with EC. According to pharmacokinetic/pharmacodynamics parameters of micafungin in HIV positive patients and MICs distribution of micafungin against <i>Candida spp</i>. in published studies, the dosage regimens of micafungin were 50, 100 and 150 mg QD iv. Monte Carlo Simulation analysed the probability of target attainment and cumulative fraction of response. The results showed that micafungin has good antifungal effect in treating HIV positive patients with EC when pathomycetes are <i>Candida albicans</i>, <i>Candida glabrata</i> or <i>Candida tropicalis</i>, in dosage at 100 mg QD and 150 mg QD.The objective of our study was to explore the possibility of the antifungal efficacy of various micafungin dosage regimens against <i>Candida spp</i> in HIV positive patients with EC. According to pharmacokinetic/pharmacodynamics parameters of micafungin in HIV positive patients and MICs distribution of micafungin against <i>Candida spp</i>. in published studies, the dosage regimens of micafungin were 50, 100 and 150 mg QD iv. Monte Carlo Simulation analysed the probability of target attainment and cumulative fraction of response. The results showed that micafungin has good antifungal effect in treating HIV positive patients with EC when pathomycetes are <i>Candida albicans</i>, <i>Candida glabrata</i> or <i>Candida tropicalis</i>, in dosage at 100 mg QD and 150 mg QD.

关 键 词：Monte Carlo Simulation MICAFUNGIN HIV Positive Patients Esophageal Candidiasis 

分 类 号：R97[医药卫生—药品]